Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Urol Int Retrieve available abstracts of 50 articles: HTML format

Single Articles

June 2023
1. LONG J, Liu Z, Liang S, Chen B, et al
   Cruciferous Vegetable Intake and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis.
   Urol Int. 2023 Jun 21:1-11. doi: 10.1159/000530435.
   PubMed     Abstract available
   
   
   
2. FERNANDEZ-ANGUITA PJ, Ventosa-Puig M, Diaz de Mera-Sanchez Migallon I, Legido-Gomez O, et al
   Value of Prostate-Specific Antigen Kinetics in Patients with Low-Risk Prostate Cancer under Active Surveillance.
   Urol Int. 2023 Jun 16:1-7. doi: 10.1159/000530963.
   PubMed     Abstract available
   
   
   April 2023
3. YOO S, Lee KH, Jamrasi P, Cho MC, et al
   Effects of Exercise on Physical Function and Quality of Life in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: High-Intensity Interval Training versus Moderate-Intensity Continuous Training.
   Urol Int. 2023 Apr 25:1-8. doi: 10.1159/000527839.
   PubMed     Abstract available
   
   
   
4. MEYER L, Bohlscheid A, Lemmer O, van de Plas J, et al
   MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 T.
   Urol Int. 2023 Apr 18:1-9. doi: 10.1159/000529873.
   PubMed     Abstract available
   
   
   
5. BAHLBURG H, Tully K, Hoffmann V, Hanske J, et al
   Avoiding Prostate Biopsies in Patients at Low Risk for Prostate Cancer: A Prospective Evaluation of a PSA-Density-Based Safety Net.
   Urol Int. 2023 Apr 14:1-6. doi: 10.1159/000529946.
   PubMed     Abstract available
   
   
   
6. QIAN L, Wang Y, Xiong Y, Ren H, et al
   LINC01002 Targets miR-650/FLNA Pathway to Suppress Prostate Cancer Progression.
   Urol Int. 2023 Apr 11:1-13. doi: 10.1159/000529947.
   PubMed     Abstract available
   
   
   March 2023
7. WANG Y, Chen X, Liu K, Liu R, et al
   Predictive Factors for Gleason Score Upgrading in Patients with Prostate Cancer after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
   Urol Int. 2023 Mar 29:1-20. doi: 10.1159/000528873.
   PubMed     Abstract available
   
   
   February 2023
8. LOPCI E, Lazzeri M, Colombo P, Casale P, et al
   Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
   Urol Int. 2023 Feb 1:1-7. doi: 10.1159/000528720.
   PubMed     Abstract available
   
   
   January 2023
9. FLEGAR L, Thoduka SG, Mahnken AH, Figiel J, et al
   Focal Therapy for Renal Cancer: Comparative Trends in the USA and Germany from 2006 to 2020 and Analysis of the German Health Care Landscape.
   Urol Int. 2023;107:396-405.
   PubMed     Abstract available
   
   
   November 2022
10. SOTOMAYOR PC, Aguilar JC, Mujica K, Zuniga A, et al
    Active Surveillance in Prostate Cancer: Current and Potentially Emerging Biomarkers for Patient Selection Criteria.
    Urol Int. 2022 Nov 7:1-13. doi: 10.1159/000527151.
    PubMed     Abstract available
    
    
    October 2022
11. BORKOWETZ A, Linxweiler J, Fussek S, Wullich B, et al
    The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.
    Urol Int. 2022 Oct 4:1-10. doi: 10.1159/000526598.
    PubMed     Abstract available
    
    
    March 2022
12. WU J, Wei Y, Li T, Lin L, et al
    DNA Methylation-Mediated Lowly Expressed AOX1 Promotes Cell Migration and Invasion of Prostate Cancer.
    Urol Int. 2022 Mar 30:1-9. doi: 10.1159/000522634.
    PubMed     Abstract available
    
    
    
13. MAKINO K, Sato Y, Takenaka R, Yamashita H, et al
    Cumulative Incidence and Clinical Risk Factors of Radiation Cystitis after Radiotherapy for Prostate Cancer.
    Urol Int. 2022 Mar 15:1-7. doi: 10.1159/000521723.
    PubMed     Abstract available
    
    
    
14. HIGASHIYAMA S, Yoshida A, Kawabe J
    Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONE Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
    Urol Int. 2022 Mar 4:1-7. doi: 10.1159/000522046.
    PubMed     Abstract available
    
    
    February 2022
15. JIN C, Bian Z, Mo F, Zhu C, et al
    Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer.
    Urol Int. 2022 Feb 18:1-9. doi: 10.1159/000519329.
    PubMed     Abstract available
    
    
    
16. SOKMEN BK, Sokmen D, Comez YI, Eksi M, et al
    Prediction of Prostate Cancer Aggressiveness Using a Novel Multiparametric Magnetic Resonance Imaging Parameter: Tumor Heterogeneity Index.
    Urol Int. 2022 Feb 11:1-8. doi: 10.1159/000521606.
    PubMed     Abstract available
    
    
    
17. BORKOWETZ A, Blana A, Bohmer D, Cash H, et al
    German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy.
    Urol Int. 2022 Feb 10:1-9. doi: 10.1159/000521882.
    PubMed     Abstract available
    
    
    
18. CAFUTA B, Distler FA, Wagner A, Pahernik S, et al
    Salvage Radiotherapy for Recurrent Prostate Cancer after High-Intensity Focused Ultrasound Therapy: Quality of Life and Functional Outcome.
    Urol Int. 2022 Feb 1:1-6. doi: 10.1159/000521660.
    PubMed     Abstract available
    
    
    January 2022
19. PORCARO AB, Panunzio A, Tafuri A, Cerrato C, et al
    The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Urol Int. 2022 Jan 26:1-12. doi: 10.1159/000521260.
    PubMed     Abstract available
    
    
    
20. HARLAND N, Russo GI, Kaufmann S, Amend B, et al
    Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy.
    Urol Int. 2022;106:90-96.
    PubMed     Abstract available
    
    
    
21. WETTERAUER C, Federer-Gsponer JR, Leboutte FDJP, Mona R, et al
    Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies.
    Urol Int. 2022;106:83-89.
    PubMed     Abstract available
    
    
    
22. HAEUSER L, Reese SW, Paciotti M, Noldus J, et al
    Surgical Complications Requiring Intervention in Open versus Minimally Invasive Radical Prostatectomy.
    Urol Int. 2022;106:51-55.
    PubMed     Abstract available
    
    
    
23. PFISTER D, Nestler T, Hartmann F, Haidl F, et al
    Feasibility and Oncologic Outcome of Salvage Surgery in Isolated Seminal Vesicle Remnants after Radical Prostatectomy.
    Urol Int. 2022;106:44-50.
    PubMed     Abstract available
    
    
    
24. DING XF, Luan Y, Xia AL, Zhu LY, et al
    Application of 16 G Biopsy Needle in Transperineal Template-Guided Prostate Biopsy.
    Urol Int. 2022;106:909-913.
    PubMed     Abstract available
    
    
    
25. SONG JA, He BM, Li HS, Yu XW, et al
    A Prospective Study Comparing Cancer Detection Rates of Transperineal Prostate Biopsies Performed by Junior Urologists versus a Senior Consultant in a Real-World Setting.
    Urol Int. 2022;106:884-890.
    PubMed     Abstract available
    
    
    
26. KOZARIS R, Hanske J, von Landenberg N, Berg S, et al
    Psychosocial Distress in the Early Recovery Period after Radical Prostatectomy.
    Urol Int. 2022;106:891-896.
    PubMed     Abstract available
    
    
    
27. ZHANG Z, Liang C
    Recurrent Prostatic Stromal Tumor of Uncertain Malignant Potential Combined with Concurrent Prostatic Adenocarcinoma: An Unusual Case.
    Urol Int. 2022;106:974-978.
    PubMed     Abstract available
    
    
    December 2021
28. CROCEROSSA F, Carbonara U, Parekh J, Urdaneta A, et al
    PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
    Urol Int. 2021 Dec 21:1-8. doi: 10.1159/000520684.
    PubMed     Abstract available
    
    
    
29. BERG S, Tully KH, von Landenberg N, Bahlburg H, et al
    How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer.
    Urol Int. 2021 Dec 20:1-6. doi: 10.1159/000520598.
    PubMed     Abstract available
    
    
    November 2021
30. FLEGAR L, Baunacke M, Buerk BT, Proschmann R, et al
    Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD(R)) for Localized Prostate Cancer.
    Urol Int. 2021 Nov 23:1-6. doi: 10.1159/000520084.
    PubMed     Abstract available
    
    
    
31. VESTRIS PG, Giwerc A, Hennequin C, Goujon A, et al
    Operative and Midterm Oncological Outcome of Focal Salvage Cryotherapy for Localized Prostate Cancer.
    Urol Int. 2021 Nov 15:1-6. doi: 10.1159/000518980.
    PubMed     Abstract available
    
    
    October 2021
32. CETIN B, Wabl CA, Gumusay O
    Optimal Treatment for Patients with Oligometastatic Prostate Cancer.
    Urol Int. 2021 Oct 26:1-10. doi: 10.1159/000519386.
    PubMed     Abstract available
    
    
    
33. GUO Y, Tian Y, Deng Y, Lu C, et al
    Diagnostic Performance of [18F]-Labeled PET/CT Tracers for Lymph Node/Bone Metastasis and Biochemical Recurrence Detection in Advanced Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Oct 13:1-19. doi: 10.1159/000518478.
    PubMed     Abstract available
    
    
    September 2021
34. LI Y, Cheng X, Zhu JL, Luo WW, et al
    Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Sep 8:1-9. doi: 10.1159/000518164.
    PubMed     Abstract available
    
    
    August 2021
35. SONG P, Shu M, Yang L, Di X, et al
    The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
    Urol Int. 2021 Aug 26:1-9. doi: 10.1159/000518113.
    PubMed     Abstract available
    
    
    
36. PETERS R, Stephan C, Jung K, Lein M, et al
    Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.
    Urol Int. 2021 Aug 25:1-6. doi: 10.1159/000517891.
    PubMed     Abstract available
    
    
    July 2021
37. TIAN B, Chunxiang E, Xiang Y, Teng P, et al
    Long Noncoding RNA LIPE-AS1 Drives Prostate Cancer Progression by Functioning as a Competing Endogenous RNA for microRNA-654-3p and Thereby Upregulating Hepatoma-Derived Growth Factor.
    Urol Int. 2021 Jul 7:1-16. doi: 10.1159/000516676.
    PubMed     Abstract available
    
    
    June 2021
38. FERRO M, Terracciano D, Musi G, de Cobelli O, et al
    Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies.
    Urol Int. 2021 Jun 24:1-8. doi: 10.1159/000516680.
    PubMed     Abstract available
    
    
    May 2021
39. KOPP D, Kopp J, Bernhardt E, Manka L, et al
    68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Urol Int. 2021 May 7:1-7. doi: 10.1159/000515651.
    PubMed     Abstract available
    
    
    
40. PORCARO AB, Siracusano S, Amigoni N, Tafuri A, et al
    The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection.
    Urol Int. 2021 May 7:1-9. doi: 10.1159/000514391.
    PubMed     Abstract available
    
    
    
41. CELIK S, Kizilay F, Yorukoglu K, Aslan G, et al
    Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey.
    Urol Int. 2021 May 5:1-9. doi: 10.1159/000513658.
    PubMed     Abstract available
    
    
    January 2021
42. MAURER V, Stahlberg J, Schiffmann I, Marks P, et al
    Continence and Complication Rates of Artificial Urinary Sphincter Devices (AMS 800) for Parkinson and Stroke Patients with Incontinence after Prostate Surgery: Retrospective Analysis of a Prospective Database.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
43. SHEN Q, Zhou Z, Liu Z, Hu S, et al
    Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
44. GOSSLER C, May M, Breyer J, Stojanoski G, et al
    High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
45. XU B, Ma BL, Peng YJ, Zhang Q, et al
    Learning Curve of an Innovative "3-Port" Laparoscopic Radical Prostatectomy: A Single-Center Analysis from 2016 to 2019.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
46. SCHMITZ-DRAGER BJ, Muhlich S, Lange C, Benderska-Soder N, et al
    Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
47. APFELBECK M, Schlenker B, Chaloupka M, Stief CG, et al
    Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
48. NAKANISHI Y, Ito M, Kataoka M, Ikuta S, et al
    Who Can Avoid Biopsy of Magnetic Resonance Imaging-Negative Lobes without Compromising Significant Cancer Detection among Men with Unilateral Magnetic Resonance Imaging-Positive Lobes?
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
49. PRATSINIS M, Babst C, Langenauer J, Schmid HP, et al
    Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    
    
50. MASSANOVA M, Robertson S, Barone B, Dutto L, et al
    The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study.
    Urol Int. 2021;105.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: